HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End

 
• By Emily Hayes

Gilead's Biktarvy (B/F/TAF) single tablet is poised to become a huge success, surpassing competitors in the HIV market by far, but the GlaxoSmithKline-backed ViiV Healthcare looks better positioned in the long run.

Red and blue arrow elevators with businessmen going up and down.

More from Market Snapshot

More from Scrip